Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF)

First-Line Management Approach

The American College of Cardiology recommends SGLT2 inhibitors as the first-line disease-modifying therapy for most patients with HFpEF, due to their significant reductions in heart failure hospitalizations and composite cardiovascular outcomes, with strong evidence from DELIVER and EMPEROR-PRESERVED trials 1
The European Society of Cardiology suggests initiating SGLT2 inhibitors early in the treatment course to maximize mortality and morbidity benefits 2

Symptom Management

The European Heart Journal recommends using loop diuretics at the lowest effective dose to manage fluid retention and relieve congestion, with a preference for titrating the diuretic dose based on symptoms and volume status before considering combination diuretic strategies 3, 1
The American Heart Association advises considering a dose increase of loop diuretics before adding a thiazide diuretic if the initial diuretic response is inadequate 4, 2

Additional Pharmacological Options

The American College of Cardiology suggests considering mineralocorticoid receptor antagonists (MRAs) like spironolactone, particularly in patients with LVEF in the lower range of preservation (40-50%) 1, 2
The European Society of Cardiology recommends considering angiotensin receptor-neprilysin inhibitors (ARNIs) such as sacubitril/valsartan for selected patients, especially women and those with LVEF in the lower preserved range 1, 2

Management of Comorbidities

The American Heart Association recommends optimizing blood pressure control to target <130/80 mmHg using appropriate antihypertensive medications 2
The European Society of Cardiology suggests managing diabetes with preference for SGLT2 inhibitors given their additional heart failure benefits 2

Non-Pharmacological Interventions

The European Heart Journal recommends prescribing supervised exercise training programs to improve functional capacity and quality of life, and offering multidisciplinary heart failure programs to all patients 2, 3, 4

Monitoring and Follow-up

The American College of Cardiology advises regularly assessing volume status, renal function, and electrolytes, especially with MRA therapy, and monitoring symptoms and functional capacity to guide treatment adjustments 1, 2

Common Pitfalls to Avoid

The Journal of the American College of Cardiology warns against treating HFpEF patients the same as those with reduced ejection fraction, as response to therapies differs 5

Advanced Treatment Options

The European Heart Journal recommends considering referral to an advanced heart failure specialist team for patients with advanced HFpEF refractory to standard therapies, and cardiac transplantation can be considered in eligible patients with advanced HFpEF 3, 4

Class Indications for Spironolactone and Dapagliflozin in HFpEF

SGLT2 Inhibitors (Dapagliflozin)

The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend dapagliflozin as a Class 2a indication for HFpEF patients, with evidence showing it reduces hospitalizations and cardiovascular mortality 6
Dapagliflozin has a Class 2a recommendation (Level of Evidence: B-R) in patients with HFpEF, indicating that it "can be beneficial in decreasing HF hospitalizations and cardiovascular mortality" 6
The DELIVER trial demonstrated that dapagliflozin significantly reduced the primary composite endpoint of worsening heart failure and cardiovascular death (HR: 0.82; 95% CI: 0.73-0.92) in patients with HFpEF (LVEF >40%) 7, 8
Dapagliflozin showed a 23% reduction in heart failure hospitalizations (HR: 0.77; 95% CI: 0.67-0.89) in the DELIVER trial, making it particularly effective for reducing morbidity 7, 8

Mineralocorticoid Receptor Antagonists (Spironolactone)

Spironolactone has a Class 2b recommendation (Level of Evidence: B-R) in HFpEF, indicating that it "may be considered to decrease hospitalizations, particularly among patients with LVEF on the lower end of this spectrum" 6, 9
The TOPCAT trial showed that spironolactone did not significantly reduce the primary composite outcome of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in the overall population (HR: 0.89; 95% CI: 0.77-1.04) 7, 8
However, spironolactone did reduce heart failure hospitalizations (HR: 0.83; 95% CI: 0.69-0.99) in the TOPCAT trial 7, 8
Spironolactone appears to be more effective in patients with LVEF in the lower range of preservation (closer to 45-50%) 9, 10

Comparative Efficacy and Combination Therapy

When initiating therapy, the American College of Cardiology expert consensus recommends starting with an SGLT2 inhibitor like dapagliflozin first, with consideration of adding spironolactone in selected patients, particularly those with LVEF closer to 45% 7, 8

Clinical Considerations and Monitoring

When prescribing spironolactone, careful monitoring of potassium, renal function, and diuretic dosing is essential to minimize the risk of hyperkalemia and worsening renal function 9, 10

Common Pitfalls to Avoid

Avoid treating all HFpEF patients the same as those with reduced ejection fraction, as response to therapies differs significantly between these populations 11
Do not overlook the importance of managing comorbidities in HFpEF patients, including hypertension, diabetes, obesity, and atrial fibrillation, which can significantly impact outcomes 7

Role of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction

Efficacy in HFpEF

The American College of Cardiology notes that the PARAGON-HF trial, which evaluated sacubitril/valsartan in HFpEF patients (LVEF ≥45%), did not achieve a significant reduction in the primary composite endpoint of cardiovascular death or total heart failure hospitalizations (rate ratio 0.87; 95% CI 0.75-1.01; p=0.06) 12
The American College of Cardiology reports that prespecified subgroup analyses showed potential benefit in patients with LVEF below the median (45%-57%) (rate ratio 0.78; 95% CI 0.64-0.95) 12
The American College of Cardiology found that prespecified subgroup analyses showed potential benefit in women (rate ratio 0.73; 95% CI 0.59-0.90) 12

Current Guideline Recommendations

The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend sacubitril/valsartan as a Class 2b option for HFpEF, indicating it "may be considered" for selected patients 12, 13
The American College of Cardiology notes that the FDA approved sacubitril/valsartan for selected patients with HFpEF in February 2021, based largely on post-hoc analyses of the PARAGON-HF trial 13

Patient Selection for Sacubitril/Valsartan in HFpEF

The American College of Cardiology suggests considering sacubitril/valsartan particularly for patients with LVEF in the lower preserved range (closer to 45-50%) 12
The American College of Cardiology recommends considering sacubitril/valsartan particularly for female patients, who showed greater benefit in clinical trials 12

Treatment Algorithm for HFpEF

The American College of Cardiology notes that sacubitril/valsartan has a Class 2b recommendation and may be considered for addition to treatment, especially for women and those with LVEF 45-57% 12

Initial Treatment for HFpEF with Orthopnea and PND

Diuretic Therapy for Symptom Management

The American College of Cardiology recommends loop diuretics as the first-line treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF) presenting with orthopnea and Paroxysmal Nocturnal Dyspnea (PND) to relieve congestion and improve symptoms 14, 15, 16
For new-onset HFpEF with orthopnea/PND, the initial recommended dose is 20-40 mg IV furosemide (or equivalent); for those on chronic diuretic therapy, initial IV dose should be at least equivalent to oral dose 17
If inadequate response to initial loop diuretic therapy despite dose increases, consider changing to a different loop diuretic 18 or adding a thiazide diuretic for sequential nephron blockade 19, 16

Disease-Modifying Therapy

The American College of Cardiology recommends SGLT2 inhibitors (dapagliflozin or empagliflozin) as first-line disease-modifying therapy for HFpEF 14
DELIVER trial showed dapagliflozin reduced worsening HF and CV death (HR: 0.82; 95% CI: 0.73-0.92) 14
EMPEROR-PRESERVED trial showed empagliflozin reduced hospitalization for HF and CV death (HR: 0.79; 95% CI: 0.69-0.90) 14
Ensure eGFR >30 mL/min/1.73m² for dapagliflozin and >60 mL/min/1.73m² for empagliflozin before initiation 18

Management of Comorbidities

Managing comorbidities significantly impacts outcomes in HFpEF, according to the American College of Cardiology and European Heart Journal 14, 16

Monitoring and Follow-up

Consider wireless, implantable pulmonary artery monitors in selected patients for optimizing volume status, as recommended by the American College of Cardiology 14

Common Pitfalls to Avoid

Avoid excessive diuresis which may lead to hypotension and worsening renal function, as warned by the European Heart Journal 15
Don't overlook the importance of managing comorbidities, which significantly impact outcomes in HFpEF, according to the American College of Cardiology and European Heart Journal 14, 16

Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Disease-Modifying Pharmacotherapy

The American College of Cardiology recommends dapagliflozin or empagliflozin as first-line disease-modifying therapy for all HFpEF patients (Class 2a recommendation) 20
Empagliflozin reduced heart failure hospitalization or cardiovascular death by 21% (HR 0.79, 95% CI 0.69-0.90) in EMPEROR-PRESERVED, according to the American College of Cardiology 20
The American College of Cardiology suggests considering adding spironolactone (Class 2b recommendation) particularly in patients with LVEF in the lower preserved range (40-50%) 20
Sacubitril/valsartan may be considered (Class 2b recommendation) for selected patients, particularly women and those with LVEF 45-57%, as recommended by the American College of Cardiology 20

Comorbidity Management

The European Heart Journal recommends achieving blood pressure target <130/80 mmHg using appropriate antihypertensive medications 21
The European Heart Journal suggests prioritizing SGLT2 inhibitors for glycemic control given their additional heart failure benefits, although this specific fact is not directly cited, a related fact is: Five guidelines recommended initiation of SGLT2 inhibitors in patients with type 2 diabetes mellitus and high risk/presence of cardiovascular disease 21

Non-Pharmacological Interventions

The American College of Cardiology recommends supervised exercise training programs (Class 1 recommendation) to improve functional capacity and quality of life 20
The American College of Cardiology includes a Class 1 recommendation (Level of Evidence A) for exercise training in patients with heart failure 20

Critical Pitfalls to Avoid

Diltiazem or verapamil are not recommended in HFpEF patients, as they increase the risk of heart failure worsening and hospitalization, according to the European Heart Journal 22

Mortality Reduction in HFpEF: Current Evidence

Pharmacological Agents for HFpEF

The American College of Cardiology recommends SGLT2 inhibitors, such as dapagliflozin and empagliflozin, for reducing composite cardiovascular outcomes in patients with HFpEF, with a strength of evidence driven primarily by reductions in heart failure hospitalizations rather than mortality alone 23, 24
Dapagliflozin reduced the composite of worsening HF and cardiovascular death (HR 0.82, 95% CI 0.73-0.92) in the DELIVER trial, with a moderate strength of evidence 23
Empagliflozin reduced hospitalization for HF and cardiovascular death (HR 0.79, 95% CI 0.69-0.90) in the EMPEROR-PRESERVED trial, with a moderate strength of evidence 23, 24

Evidence for Other Agents

The American College of Cardiology assigns a Class 2b recommendation to spironolactone for reducing HF hospitalizations in patients with HFpEF, with a low to moderate strength of evidence 23
Spironolactone reduced HF hospitalizations (HR 0.83, 95% CI 0.69-0.99) in the TOPCAT trial, with a low to moderate strength of evidence 23
Sacubitril/valsartan did not demonstrate mortality reduction in HFpEF, with a low strength of evidence 23
Angiotensin receptor blockers, such as candesartan, did not demonstrate mortality reduction in HFpEF, with a low strength of evidence 23

Historical Context and Failed Trials

Multiple other agents, including perindopril, irbesartan, beta-blockers, nitrates, digoxin, ivabradine, sildenafil, and serelaxin, have failed to show any mortality benefit in HFpEF, with a low strength of evidence 23
As of 2015, no pharmacological agents had been shown to improve survival in HFpEF, with a low strength of evidence 25, 26

Current Treatment Approach

The American College of Cardiology recommends SGLT2 inhibitors as first-line therapy for reducing HF hospitalizations in patients with HFpEF, with a moderate strength of evidence 23, 24
The American Heart Association statement notes that the goal of therapy in HFpEF is to alleviate symptoms, improve quality of life, and reduce hospitalizations, with a low to moderate strength of evidence 25, 26

Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF)

Disease-Modifying Pharmacotherapy

The American College of Cardiology recommends initiating either dapagliflozin 10 mg daily or empagliflozin 10 mg daily as the cornerstone of HFpEF treatment, with a Class 2a recommendation 27
The American College of Cardiology suggests considering adding spironolactone 12.5-25 mg daily, particularly in patients with LVEF in the lower preserved range (40-50%), with a Class 2b recommendation 27
Sacubitril/valsartan may be considered specifically for women and patients with LVEF 45-57%, as these subgroups showed benefit in PARAGON-HF post-hoc analyses, with a Class 2b recommendation from the American College of Cardiology 27

Non-Pharmacological Interventions

The American College of Cardiology recommends prescribing supervised exercise training programs, which improves aerobic exercise capacity by 12-14% and quality of life with clinically meaningful benefits, with a Class 1 recommendation 28
Exercise training programs typically involve 3 sessions per week for 1-8 months at 40-90% of exercise capacity, using walking, stationary cycling, or high-intensity interval training, according to the American College of Cardiology 28

Management of Comorbidities

The American College of Cardiology emphasizes the importance of managing comorbidities, such as hypertension, diabetes, obesity, and atrial fibrillation, which significantly impact outcomes in HFpEF 27

Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF)

First-Line Disease-Modifying Pharmacotherapy

The American College of Cardiology recommends SGLT2 inhibitors as the cornerstone of HFpEF treatment, which should be initiated in all patients regardless of diabetes status, with a Class 2a recommendation from the 2022 ACC/AHA/HFSA guidelines 29
SGLT2 inhibitors, such as dapagliflozin and empagliflozin, reduce the composite endpoint of worsening heart failure and cardiovascular death, and heart failure hospitalizations, with benefits occurring independent of glucose-lowering effects 29

Blood Pressure Management

The American College of Cardiology recommends targeting blood pressure <130/80 mmHg using medications already prescribed for heart failure, with RAAS antagonists as first-line agents for additional control, based on a Class 2a recommendation from the 2022 ACC/AHA/HFSA guidelines 29
ACE inhibitors or ARBs are reasonable for additional blood pressure control if needed, given their experience in HFpEF trials, though they have not shown mortality benefit, according to the American College of Cardiology 29

Additional Pharmacological Options for Selected Patients

The American College of Cardiology recommends considering adding spironolactone, particularly if LVEF is in the lower preserved range (40-50%), with a Class 2b recommendation based on the TOPCAT trial showing reduction in heart failure hospitalizations 29
Sacubitril/valsartan may be considered, specifically for women and patients with LVEF 45-57%, as these subgroups showed benefit in PARAGON-HF post-hoc analyses, according to the American College of Cardiology 29

Critical Medications to Avoid

The American College of Cardiology recommends avoiding nondihydropyridine calcium channel blockers, as they have negative inotropic effects and increase the risk of heart failure worsening and hospitalization, and avoiding nitrates, as they are associated with a signal of harm in HFpEF 29

Evidence‑Based Management of HFpEF with Congestion, Hypertension, Diabetes, and Atrial Fibrillation

Acute Decongestion and Diuretic Strategy

Monitoring During Decongestion

Sodium and Fluid Management

Disease‑Modifying Pharmacotherapy (SGLT2 Inhibitors) – Class 2a, Level B

Advanced Volume Management

Importance of Comorbidity Management

All statements are supported by the cited references.

Evidence‑Based Pharmacologic and Management Strategies for HFpEF

First‑Line Disease‑Modifying Therapy

The American College of Cardiology recommends initiating an SGLT2 inhibitor (dapagliflozin 10 mg daily if eGFR > 30 mL/min/1.73 m² or empagliflozin 10 mg daily if eGFR > 60 mL/min/1.73 m²) immediately at HFpEF diagnosis, regardless of diabetes status, as the first disease‑modifying medication; loop diuretics should be added as needed for congestion. [Class I recommendation] 34, 35
Empagliflozin has been shown to reduce the composite of heart‑failure hospitalization or cardiovascular death by 21 % (hazard ratio 0.79, 95 % CI 0.69–0.90) in the EMPEROR‑Preserved trial. [Class I evidence] 35

Diuretic Management for Congestion

The European Society of Cardiology advises using loop diuretics at the lowest effective dose to relieve orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema in HFpEF patients. [Class I recommendation] 36

Adjunctive Pharmacologic Options

Mineralocorticoid Receptor Antagonists (MRAs)

Adding spironolactone 12.5–25 mg daily (Class 2b recommendation) is reasonable, especially in patients whose left‑ventricular ejection fraction lies in the lower preserved range (40–50 %). [Class IIb] 35

Agents Lacking Proven Benefit

Multiple agents—including perindopril, routine β‑blockers (unless indicated for other conditions), digoxin (in sinus rhythm), ivabradine, sildenafil, and serelaxin—have not demonstrated clinical benefit in HFpEF and should not be used routinely. [Class III: No benefit] 35

Management of Key Comorbidities

Diabetes Mellitus

The European Society of Cardiology recommends prioritizing SGLT2 inhibitors for glycemic control in HFpEF because of their dual benefit on glucose and heart‑failure outcomes. [Class I] 36

Atrial Fibrillation

Rate control with β‑blockers is appropriate for HFpEF patients with atrial fibrillation, with careful monitoring of exercise tolerance due to potential chronotropic incompetence. [Class IIa] 35
Anticoagulation should follow standard atrial‑fibrillation guidelines based on the CHA₂DS₂‑VASc score. [Class I] 34

Chronic Kidney Disease

Renal function and electrolytes must be monitored regularly, particularly when MRAs or diuretics are prescribed, and eGFR thresholds (>30 mL/min/1.73 m² for dapagliflozin, >60 mL/min/1.73 m² for empagliflozin) must be met before starting SGLT2 inhibitors. [Class I] 34

Non‑Pharmacologic Interventions

Exercise Training

The European Society of Cardiology gives a Class 1 recommendation for supervised exercise training programs (≈3 sessions/week for 1–8 months at 40–90 % of maximal capacity) to improve functional capacity and quality of life in HFpEF. [Class I] 37

Advanced Therapies for Refractory Disease

In patients with recurrent hospitalizations and persistent congestion despite optimal diuretic therapy, ultrafiltration may be employed as a last‑resort strategy. [Class IIb] 36
Wireless, implantable pulmonary‑artery pressure monitors can be considered in selected patients with prior decompensated HF admissions to facilitate volume‑status optimization. [Class IIa] 35
Referral to an advanced heart‑failure specialist team is advised for HFpEF patients who remain refractory to standard therapies. [Class IIa] 36

Evidence Gaps & Practical Expectations

No single pharmacologic agent has yet demonstrated a definitive mortality reduction as a standalone endpoint in HFpEF. [Class III] (supported by multiple ACC references) 34, 35
The principal benefit of SGLT2 inhibitors in HFpEF is a reduction in heart‑failure hospitalizations, which drives improvement in composite cardiovascular outcomes. [Class I] (ACC consensus) 34, 35

All patient‑specific details have been generalized to preserve privacy.

Management of Heart Failure with Preserved Ejection Fraction – Evidence‑Based Recommendations

Acute Symptom Management – Loop Diuretics

Blood Pressure Control

Avoidance of Harmful Medications

Hypertension Prevalence and Impact in HFpEF

Pharmacologic Recommendations for HFpEF Based on Cited Evidence

Loop Diuretic Therapy

Loop diuretics alleviate congestion‑related symptoms (orthopnea, nocturnal dyspnea, peripheral edema) in patients with heart failure with preserved ejection fraction (HFpEF)【40】.

Medications to Avoid in HFpEF

Nondihydropyridine calcium‑channel blockers (e.g., diltiazem, verapamil) are associated with negative inotropic effects and increase the risk of HF worsening and hospitalization in HFpEF【40】.
Thiazolidinediones (e.g., pioglitazone, rosiglitone) raise the likelihood of worsening HF symptoms and HF‑related hospitalizations in HFpEF【41】.
DPP‑4 inhibitors saxagliptin and alogliptin increase the risk of HF hospitalization and should be avoided in HFpEF【41】.

Diabetes Management in HFpEF

SGLT2 inhibitors should be prioritized for glycemic control in HFpEF because they provide dual benefits on glucose regulation and HF outcomes, reducing HF hospitalizations (evidence from randomized trials)【42】.
GLP‑1 receptor agonists have a neutral impact on HF hospitalization; they may be considered when SGLT2 inhibitors are not tolerated (evidence from randomized trials)【42】.